Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD
Anti-CD20 Mechanism of Action The mechanism of action for anti-CD20 therapies revolves around their targeted approach to B cells, a […]
